IMTX (Immatics NV) Other Financing: $-8.82 Mil (TTM As of Mar. 2026)


IMTX Immatics NV IMTX
60 GF Score
Price $9.53
GF Value $3.57
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Immatics NV Other Financing?

Immatics NV IMTX -0.05% 60 Other Financing is $-8.82 Mil as of Mar. 2026. GuruFocus rates IMTX with a GF Score™ of 60/100 and a GF Value™ of $3.57 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Immatics NV's Other Financing for the three months ended in Mar. 2026 was $-0.63 Mil.

Immatics NV's Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.82 Mil.

Immatics NV Other Financing Historical Data

* Premium members only.

The historical data trend for Immatics NV's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immatics NV Other Financing Chart

Immatics NV Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial 0.00 -8.40 -2.22 -22.32 -8.20

Immatics NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -0.00 -8.20 -0.63
IMTX
60GF Score
Immatics NV IMTX
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Immatics NV Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of $-8.82 Mil mean?
Immatics NV (IMTX) has a Other Financing of $-8.82 Mil as of Mar. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Immatics NV and its competitors.
Is Immatics NV's Other Financing too high?
Immatics NV's current Other Financing is $-8.82 Mil. Overall, Immatics NV has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's Other Financing compare to MNKD and JBIO?
Immatics NV's Other Financing of $-8.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Immatics NV and its competitors. Immatics NV's current Other Financing is $-8.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.57, compared to a current price of $9.53 — trading 166.8% above its estimated fair value. The current Other Financing is $-8.82 Mil. Immatics NV's overall GF Score™ is 60/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Immatics NV (IMTX), the current Other Financing is $-8.82 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immatics NV (IMTX) Overvalued in 2026?

Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued. The current stock price of $9.53 is trading 166.8% above its estimated GF Value™ of $3.57. GuruFocus considers Immatics NV to be Significantly Overvalued.

Key valuation signals for IMTX:

  • Other Financing: $-8.82 Mil
  • GF Value™: $3.57 vs. price of $9.53 (166.8% above fair value)
  • GF Score™: 60/100 with 4 warning signs

No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immatics NV Business Description

Other Exchanges 4A3:Germany
Address Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
60GF Score

Get the complete analysis for IMTX

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.53
Price
$3.57
GF Value